{"filings":[{"id":68002,"accession_number":"0001104659-26-060232","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2026-05-13T20:06:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.","Net loss narrowed to $2.2M ($0.08 loss per share) from $4.1M ($0.18 loss per share) YoY.","Adjusted EBITDA turned positive at $0.6M ($0.02 per share) vs negative $0.9M in Q1 2025.","Cash increased to $27M; gross margin 61% impacted by $1.3M non-cash API write-down.","SG&A down $0.5M to $10.1M due to lower Emrosi launch costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96400,"accession_number":"0001104659-26-046158","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical expands Emrosi payer coverage to ~85% of US commercial lives after third GPO contract","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Secured contract with third major GPO, expanding Emrosi commercial access from ~100M to >150M lives as of April 1, 2026.","Approximately 85% of all US commercial lives now have access to Emrosi for treatment of inflammatory rosacea lesions.","CEO cites milestone for Emrosi launch; expects less reliance on copay bridging and improved profitability as formulary adoption grows.","Focus remains on converting access into coverage through health plan formulary adoption throughout 2026 and beyond."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110277,"accession_number":"0001104659-26-034506","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.","Gross margin improved to 66.2% from 62.8%, driven by higher-margin Emrosi and Qbrexza.","Adjusted EBITDA positive $2.9M ($0.12 per diluted share) vs $0.8M in prior year.","SG&A rose 10% to $44.4M due to Emrosi commercialization costs.","Accutane revenue declined $6.5M amid competitive pressures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126859,"accession_number":"0001104659-25-110344","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q3 2025 revenue $17.6M (+21% YoY); Emrosi sales $4.9M, prescriptions up 146%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net revenues $17.6M, up 21% YoY from $14.6M; driven by Emrosi launch.","Emrosi net sales $4.9M; prescriptions increased 146% sequentially vs Q2 2025.","Net loss narrowed to $2.3M ($0.09/sh) from $2.4M ($0.12/sh) in Q3 2024.","Adjusted EBITDA improved to positive $1.7M vs $0.3M in prior-year quarter.","Gross margin 67.4% vs 69.4% in Q3 2024 (prior year benefited from one-time adjustments)."],"consensus_eps_estimate":-0.0485,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":45779000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143656,"accession_number":"0001104659-25-093891","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Journey Medical extends term loan maturity to June 2028 and lowers revenue threshold for deferred repayment to $60M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of $25M Term Loan extended from Dec 27, 2027 to June 27, 2028.","If trailing 12-month revenue > $60M as of Dec 31, 2025 (down from $70M), principal repayment deferred to Feb 2027.","Without revenue trigger, quarterly repayment begins Feb 2026 at 7.5% of principal.","With revenue trigger, quarterly repayment at 10% starting Feb 2027 (down from 15%).","All $25M drawn; agreement amended with SWK Funding LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143655,"accession_number":"0001104659-25-084879","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Journey Medical signs new ATM agreement to sell up to 3.75M common shares, ends prior B. Riley facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with B. Riley and Lake Street allows sale of up to 3,750,000 shares of common stock at the market.","Agents will receive a commission of 3.0% of gross proceeds from sales under the new agreement.","Prior Sales Agreement with B. Riley terminated effective August 28, 2025; 4,121,318 shares sold under it since December 2022.","Company is not obligated to make any sales; offering terminates upon sale of all shares or agreement termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143654,"accession_number":"0001104659-25-076825","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.","Total net product revenue $15.0M, up slightly from $14.9M year-over-year.","Gross margin improved to 67% from 61% due to favorable product mix and lower COGS.","SG&A expenses rose to $11.9M from $10.3M, driven by Emrosi launch costs.","Adjusted EBITDA loss of $0.5M vs positive $0.3M in prior year period."],"consensus_eps_estimate":-0.1071,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":28148000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143653,"accession_number":"0001104659-25-067767","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical expands Emrosi payer coverage to 65% of commercial lives from 29% in May 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Emrosi now has pharmacy benefit coverage for 65% of 187 million U.S. commercial lives, up from 29% in May 2025.","Expanded coverage expected to drive further growth in total prescription demand for rosacea treatment.","CEO cites targeted contracting strategy, increasing prescription demand, and superior clinical data as drivers.","Emrosi is available by prescription at specialty pharmacy chains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161869,"accession_number":"0001104659-25-063032","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Journey Medical stockholders approve officer exculpation charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended certificate of incorporation effective June 24, 2025, adding officer exculpation.","Six directors elected: Rosenwald, Maraoui, Herskowitz, Smith, Toledano, Pearce; all received >25.4M votes for.","KPMG LLP ratified as independent auditor for FY 2025 with 32.5M votes for, 10,433 against.","Charter amendment approved with 25.4M for, 799K against, 6.3M broker non-votes.","Quorum of 85% of eligible shares represented; 19.7M common and 6M Class A shares voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161868,"accession_number":"0001104659-25-061956","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical to join Russell 2000 and Russell 3000 indexes effective June 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joins Russell 2000 and Russell 3000 indexes after market close on June 27, 2025.","Inclusion from 2025 annual Russell reconstitution; expected to boost investor visibility.","CEO states Emrosi launch off to strong start; believes 2025 could be transformational.","Over $10.6 trillion in assets benchmarked to Russell U.S. indexes globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161867,"accession_number":"0001104659-25-048502","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.","Revenue $13.1M, flat YoY; includes $2.1M from Emrosi launch.","Gross margin improved to 64% from 54% YoY; R&D costs nil vs $7.9M.","Cash $21.1M at March 31, 2025 (vs $20.3M at Dec 31, 2024).","Emrosi commercial launch started April 7; Phase 3 results published in JAMA Dermatology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":13139000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161866,"accession_number":"0001104659-25-031463","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Journey Medical appoints Ramsey Alloush as COO; remains General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ramsey Alloush, previously General Counsel, appointed COO effective April 1, 2025.","He continues as General Counsel; base salary $392,945 with 50% bonus target.","Alloush led the Company's IPO, major transactions, and Hatch-Waxman litigations.","Press release cites imminent Emrosi launch and commitment to operational excellence.","No family relationships or material transactions with directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179926,"accession_number":"0001104659-25-028226","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.","Net loss $14.7M ($0.72/sh) vs $3.9M loss prior year; adjusted EBITDA $0.8M vs $15.6M.","FDA approved Emrosi (minocycline) for rosacea Nov 2024; distribution started, first prescriptions filled, full promo expected April 2025.","Met all 2024 financial guidance: product revenue $55-60M, SG&A $39-42M, R&D $9-10M.","Non-GAAP adjusted EBITDA per share $0.04 basic, $0.03 diluted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179925,"accession_number":"0001104659-25-026878","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical launches Emrosi for rosacea; first prescriptions filled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Emrosi (40 mg minocycline HCl modified-release) launched for inflammatory lesions of rosacea in adults.","First prescriptions filled; initial distribution to specialty pharmacy chains ongoing.","FDA approval was obtained in November 2024; Emrosi is the lowest-dose oral minocycline for rosacea.","Clinical trials showed significantly superior outcomes vs. Oracea and placebo with comparable safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179924,"accession_number":"0001104659-25-009641","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Journey Medical expects $20.3M cash; reaffirms FY2024 revenue guidance $55-60M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Cash and cash equivalents expected to be $20.3 million as of December 31, 2024.","Reaffirms FY2024 guidance: net product revenue $55-60M, SG&A $39-42M, R&D $8-10M.","Hosts Feb 5, 2025 conference call to update commercial launch plan for Emrosi (minocycline HCl ER 40 mg).","Investor presentation (Exhibit 99.1) attached but specific slide content not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":56134000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196727,"accession_number":"0001104659-24-116762","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.","Net product revenues $14.6M, down 4% YoY; Qbrexza sales up 29% to $7.6M.","Net loss $2.4M ($0.12/sh) vs net income $16.8M ($0.91/sh) in Q3 2023 (included $19M license payment).","Adjusted EBITDA $0.3M ($0.01/sh) vs $20.8M ($1.13/sh) in Q3 2023.","Gross margin improved to 63.9% from 57.9% due to lower inventory charges and royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":42514000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196726,"accession_number":"0001104659-24-113659","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"FDA approves Emrosi for rosacea; Q3 prelim revenue $14.6M, net loss $2.4M; FY guidance unchanged","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Emrosi (minocycline HCl ER 40 mg) for inflammatory lesions of rosacea in adults; initial supply expected late Q1 or early Q2 2025.","Q3 2024 prelim net product revenue $14.6M (vs $15.3M YoY); net loss $2.4M (vs $16.8M net income Q3 2023 which had $19.3M license payment).","Nine-month 2024 net product revenue $42.5M (vs $44.4M); net loss $16.2M (vs $1.7M); R&D $9.6M includes $4.1M FDA fee and $3.0M milestone to DRL.","FY 2024 guidance unchanged: net revenue $55-60M, SG&A $39-42M, R&D $9-10M.","Approval triggered $15M milestone to Dr. Reddy's; mandatory $5M draw under SWK Credit; expects $4.4M recovery from 2021 cyber incident in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213022,"accession_number":"0001104659-24-088345","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.","Net loss reduced to $3.4M ($0.17/sh) from $8.4M ($0.46/sh) in Q2 2023.","Adjusted EBITDA positive $0.3M vs negative $0.6M in prior-year quarter.","DFD-29 NDA for rosacea under FDA review with PDUFA goal date November 4, 2024.","Appointed Joseph M. Benesch as permanent CFO and Michael C. Pearce to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":27885000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213021,"accession_number":"0001104659-24-079596","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","2.03","5.02"],"status":"ready","headline":"Journey Medical increases credit facility to $25M, appoints new director Michael C. Pearce","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit facility increased from $20M to $25M; additional $5M available upon FDA approval of DFD-29 by June 30, 2025.","Term loan matures Dec 27, 2027; interest = 3-month SOFR (floor 5%) + 7.75%.","Principal repayment starts Feb 2026 at 7.5% quarterly; delayed if trailing revenue >$70M as of Dec 2025.","Appointed Michael C. Pearce to Board (size now six); receives 30,000 RSUs, $50K annual RSU grant, $50K cash retainer.","Adopted non-qualified deferred compensation plan for non-employee directors and select executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232142,"accession_number":"0001104659-24-074743","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Journey Medical shareholders approve 3M share increase and 10-year extension of 2015 stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved an amendment to the 2015 Stock Incentive Plan adding 3,000,000 shares, for a total of 10,642,857 shares authorized.","Plan expiration extended by 10 years to May 27, 2035.","All five director nominees re-elected; KPMG LLP ratified as auditor for 2024.","Proposals received strong support: ~95% of votes cast for plan amendment, 99.9% for auditor ratification.","The plan amendment became effective immediately upon stockholder approval on June 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232141,"accession_number":"0001104659-24-060513","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.","Non-GAAP Adjusted EBITDA turned positive at $11K ($0.001 per share) vs negative $5.3M prior year.","R&D expenses rose to $7.9M from $2.0M due to $4M FDA filing fee and $3M DRL milestone for DFD-29.","SG&A cut 37% to $8.4M; Qbrexza and Accutane each grew >20% YoY.","FDA accepted DFD-29 NDA for rosacea; PDUFA target action date November 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":13030000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232140,"accession_number":"0001104659-24-055725","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Journey Medical appoints Joseph Benesch as permanent CFO effective April 26","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Benesch had served as interim CFO since January 2023 and as Corporate Controller since November 2021.","Compensation remains unchanged; any future changes will be determined by Board/Compensation Committee.","Benesch brings over 25 years of public/private accounting and life sciences experience, including prior CFO roles at Teligent and Torrent.","CEO Claude Maraoui cited Benesch's leadership as key for upcoming milestones, including potential DFD-29 FDA decision for rosacea."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250407,"accession_number":"0001104659-24-037318","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.","Net product revenues fell 16% to $59.7M due to generic competition and Ximino discontinuation.","Net loss improved to $3.9M ($0.21 loss per share) from $29.6M ($1.69 loss per share) in 2022.","Adjusted EBITDA turned positive to $15.6M ($0.85 basic EPS) from negative $7.3M in 2022.","NDA for rosacea candidate DFD-29 accepted by FDA; PDUFA goal date set for November 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}